Awarded contract

NHS Branded Medicines Tranche Framework for London and South of England

Details

Buyer: NHS England
Supplier(s): 28 suppliers
AVENTIS PHARMA LIMITED
Accord UK Ltd
Astra Zeneca UK Limited
BIOSIMILAR COLLABORATIONS IRELAND LIMITED
Celltrion Healthcare United Kingdom Ltd
Chugai Pharma UK Ltd
Dr Reddy's Laboratories (UK) Ltd
Eli Lilly and Company Ltd
Galapagos Biotech Ltd
GEDEON RICHTER (UK) LIMITED
GLAXOSMITHKLINE UK LIMITED
Janssen Cilag Ltd
LEO Pharma
Manx Healthcare Ltd
MERCK SHARP & DOHME (UK) LIMITED
Napp Pharmaceuticals Ltd
Novartis Pharmaceutical UK Ltd
Organon Pharmaceuticals UK Ltd
Orifarm UK
Pfizer Liimted
Ranbaxy (UK) Ltd
Roche Products Ltd
Swedish Orphan Biovitrum Ltd (Sobi UK Ltd)
Takeda UK Limited
Teva UK Ltd
Thornton and Ross
UCB Pharma Ltd
Zentiva Pharma UK Ltd
Value: £39
Topic: Pharmaceutical products
Published: 20 August 2024
Source: uk:find_a_tender

Tender description

NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024<br/>Offer reference number: CM/PHR/22/5689<br/>CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.<br/>CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.<br/>CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Lot 1: CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South - Lot 1 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 2: CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South - Lot 2 CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 3: CM/PHR/22/5689/03 - Omalizumab and Diroximel Fumarate for MAE & NOFE - Lot 3 CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Timeline

Completed: Award date22 July 2024
Completed: Award published20 August 2024
Current notice

About the buyer

NHS England runs the NHS in England, and buys as a central healthcare organisation with its own team of procurement professionals. Every tender is advertised on Atamis, the NHS's single eCommercial system, and larger contracts appear on Find a Tender. Much of this procurement flows through framework agreements and the Crown Commercial Service. Clinical services are commissioned directly or through the Provider Selection Regime. Seven regional teams support the commissioning of healthcare services across the country. The central commercial function that develops procurement strategy for the whole NHS sits here.

UK health spending has nearly quadrupled to £241.8bn in 2024/25, £20bn up on the year before. £140.6bn of that went to procurement, the biggest sector of UK public spending and the fastest-growing.

Over the past 5 years, most of NHS England's contract awards have been in education and training, health and social work, and IT services.

Relevant CPV codes

33600000 · Pharmaceutical products

Decision makers

Connect with the people behind this procurement.

Job title	Phone number	Work email
Head of Procurement	+44 •••• ••••••	••••••••@nhs-england.gov
Commercial Director	+44 •••• ••••••	••••••••@nhs-england.gov
Procurement Manager	+44 •••• ••••••	••••••••@nhs-england.gov
Category Lead	+44 •••• ••••••	••••••••@nhs-england.gov
Senior Buyer	+44 •••• ••••••	••••••••@nhs-england.gov
Contracts Manager	+44 •••• ••••••	••••••••@nhs-england.gov